17基因基因组前列腺评分在Canary主动监测队列中的结果
本研究在Canary主动监测研究(PASS)多中心队列中评估17基因Oncotype DX基因组前列腺评分(GPS)对低危前列腺癌患者不良病理(AP)的预测价值。
要点
- GPS与AP的独立关联在调整PSAD后未达统计学显著。
- GPS与主动监测期间活检升级无显著关联。
- GPS加入PSAD和GG模型未显著改善AP风险分层。
核心结论
- 在初始主动监测后,GPS与不良病理的独立关联未达统计学显著。
- GPS与监测活检升级无关联。
- 在PSAD和诊断GG模型中加入GPS未显著改善AP风险分层。
研究设计与样本
- 多中心主动监测队列研究,纳入Canary前列腺主动监测研究(PASS)8个中心的男性。
- 获取诊断活检组织进行GPS检测,主要终点为主动监测后行根治性前列腺切除术(RP)患者的不良病理(GG≥3或≥pT3a)。
- 采用区间删失数据多变量回归模型评估AP与GPS的关联,并用逆概率删失加权调整信息性删失。
- 使用Cox比例风险模型评估GPS与监测活检升级时间的关联。
主要发现
- 共432名男性获得GPS结果,中位随访4.6年;101人在中位监测2.1年后行RP,其中52人存在AP。
- 167人(39%)在后续活检中升级。
关键数值与推荐
- 不良病理定义为Gleason Grade Group≥3或≥pT3a。
临床怎么用
- 对于低危前列腺癌主动监测患者,GPS单独使用可能不足以独立预测不良病理。
- GPS联合PSAD和诊断GG可能提供风险分层,但未显著优于临床变量 alone。
- GPS不应用于预测监测活检升级。
局限性
- GPS与AP的独立关联未达统计学显著,可能受样本量限制。
- 研究为观察性队列,可能存在未测量混杂。
- GPS检测仅在部分患者中进行,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 17-gene Oncotype DX Genomic Prostate Score (GPS) test predicts adverse pathology (AP) in patients with low-risk prostate cancer treated with immediate surgery. We evaluated the GPS test as a predictor of outcomes in a multicenter active surveillance cohort. MATERIALS AND METHODS: Diagnostic biopsy tissue was obtained from men enrolled at 8 sites in the Canary Prostate Active Surveillance Study. The primary endpoint was AP (Gleason Grade Group [GG] ≥ 3, ≥ pT3a) in men who underwent radical prostatectomy (RP) after initial surveillance. Multivariable regression models for interval-censored data were used to evaluate the association between AP and GPS. Inverse probability of censoring weighting was applied to adjust for informative censoring. Predictiveness curves were used to evaluate how models stratified risk of AP. Association between GPS and time to upgrade on surveillance biopsy was evaluated using Cox proportional hazards models. RESULTS: GPS results were obtained for 432 men (median follow-up, 4.6 years); 101 underwent RP after a median 2.1 years of surveillance, and 52 had AP. A total of 167 men (39%) upgraded at a subsequent biopsy. GPS was significantly associated with AP when adjusted for diagnostic GG (hazards ratio [HR]/5 GPS units, 1.18; 95% CI, 1.04 to 1.44; P = .030), but not when also adjusted for prostate-specific antigen density (PSAD; HR, 1.85; 95% CI, 0.99 to 4.19; P = .066). Models containing PSAD and GG, or PSAD, GG, and GPS may stratify risk better than a model with GPS and GG. No association was observed between GPS and subsequent biopsy upgrade (P = .48). CONCLUSION: In our study, the independent association of GPS with AP after initial active surveillance was not statistically significant, and there was no association with upgrading in surveillance biopsy. Adding GPS to a model containing PSAD and diagnostic GG did not significantly improve stratification of risk for AP over the clinical variables alone.
引用
- Lin DW, Zheng Y, McKenney JK, et al. 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. J Clin Oncol. 2020. PMID: 32130059. doi:10.1200/JCO.19.02267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。